This case suggests that some ER+ErbB2- basal-type breast cancer patients could benefit from neoadjuvant chemoimmunotherapy, and we eagerly await further evidence from KEYNOTE-756, CheckMate 7FL, and the MammaPrint-tailored S2206 randomized phase III trials. The gene discussed is ERBB2; the disease is breast carcinoma.